Dzhamilya Yu. Kurmaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dzhamilya Yu. Kurmaeva has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- A S Mashkov
Voronovskoye Moscow Clinical Center for Infectious Diseases
1 shared publication - A Y Karpunin
Regional Clinical Hospital
1 shared publication - A. R. Lashkina
Penza State University
1 shared publication - Alina S. Sushko
Penza State University
1 shared publication - Anna Ivanovna Simakova
Pacific State Medical University
1 shared publication - B V Berezhanskiy
R-Pharm JSC
1 shared publication
Latest Publications
- Open Access
- 18 September 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 25 (3) , 10-15
Treatment of a comorbid patient with severe hemorrhagic fever with renal syndrome
The development of drugs for effective antiviral therapy of hemorrhagic fever with renal syndrome remains a highly important problem still unresolved today, since drugs with non-specific effects on the infectious process are still used in widespread clinical practice. At the same time, presence of concomitant diseases and a burdened medical history make certain adjustments to therapeutic tactics. The article presents a clinical case of treatment of a comorbid patient with severe hemorrhagic fever with renal syndrome, acute kidney injury caused by acute tubulointerstitial nephritis in the presence of a number of concomitant diseases.
- 18 September 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 25 (3) , 10-15
Open AccessTreatment of a comorbid patient with severe hemorrhagic fever with renal syndrome
The development of drugs for effective antiviral therapy of hemorrhagic fever with renal syndrome remains a highly important problem still unresolved today, since drugs with non-specific effects on the infectious process are still used in widespread clinical practice. At the same time, presence of concomitant diseases and a burdened medical history make certain adjustments to therapeutic tactics. The article presents a clinical case of treatment of a comorbid patient with severe hemorrhagic fever with renal syndrome, acute kidney injury caused by acute tubulointerstitial nephritis in the presence of a number of concomitant diseases.
- Open Access
- 15 December 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (12) , 148-154
Experience of olokizumab use in COVID-19 patients
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it. Aim.To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting. Materials and methods.The analysis included data of 610 subjects aged 55.0812.68 years who received olokizumab at a single dose of 160 mg/mL 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.2311.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome. Results.If a cytokine storm occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation. Conclusion.The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.
- 15 December 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (12) , 148-154
Open AccessExperience of olokizumab use in COVID-19 patients
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it. Aim.To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting. Materials and methods.The analysis included data of 610 subjects aged 55.0812.68 years who received olokizumab at a single dose of 160 mg/mL 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.2311.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome. Results.If a cytokine storm occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation. Conclusion.The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.